The acquisition also includes MBI scanner designs, manufacturing tools, instructions, related patents, and the installed-base service business.
The Discovery NM750b is installed at various sites globally. SmartBreast will be responsible for manufacturing, marketing, and distributing the MBI scanner, rebranded to EVE CLEAR SCAN e750.
MBI saves lives by early detection of breast cancer in women with dense breasts, comprising approximately 40% American, European, and African women and 70% Asian women.
It sees through dense breast tissue and identifies cancers, which mammography fails to notice.
GE Healthcare Nuclear Medicine general manager Erez Levy said: “GE Healthcare ’s MBI system has developed a positive reputation for helping physicians with the detection of cancer lesions in dense breast tissue.
“We are proud of this system’s legacy and will continue to support its mission with our world-class Cadmium Zinc Telluride (CZT) detectors for SmartBreast ’s use in the MBI system.”
According to a published clinical study with one-year follow up of 1,585 women with dense breasts, Mayo Clinic researchers noted that mammography found 3.2 cancers per 1,000 women with dense breasts.
Addition of low-dose MBI improved the number of cancers found to 12 per 1,000.
SmartBreast CEO Dr James Hugg said: “We will become the largest global player in secondary screening and diagnostics for women with dense breasts by providing the most effective tool for locating and diagnosing cancers occult on mammography.
“We have acquired Dilon’s and also GE Healthcare ’s MBI product lines, consolidating clinically proven reliable products with 217 installations globally.”
The companies have not disclosed the financial terms of the deal.
Last November, GE Healthcare announced plans to acquire Swedish start-up Prismatic Sensors in an effort to expand its portfolio in photon-counting CT (PCCT) technology.